Brought to you by 
Stressgen, Genzyme form cancer gene therapy JV
08 Mar 2004
Executive Summary
Stressgen (stress proteins) and Genzyme will form a cancer gene therapy joint venture that will combine Stressgen's stress genes and Genzyme's gene therapy vectors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Stressgen, Genzyme form cancer gene therapy JV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice